

# **AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA516)**

## **NICE GUIDANCE ISSUED FEBRUARY 2018**

(Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)

### **Final Appraisal Recommendation**

**Advice No: 4014 – December 2014**

**Cabozantinib (Cometriq<sup>®</sup>▼) 20 mg and 80 mg hard capsules**

**Submission by Swedish Orphan Biovitrum Ltd/  
TMC Pharma Services Ltd**

### **Recommendation of AWMSG**

**Cabozantinib (Cometriq<sup>®</sup>▼) is recommended as an option for use within NHS Wales for the treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma. For patients in whom Rearranged during Transfection (RET) mutation status is not known or is negative, a possible lower benefit should be taken into account before individual treatment decision.**

#### **Additional note(s):**

- AWMSG acknowledged that the AWMSG criteria for appraising life-extending, end-of-life medicines applied to cabozantinib (Cometriq<sup>®</sup>▼) for the indication under consideration.
- AWMSG considered that cabozantinib (Cometriq<sup>®</sup>▼) satisfied the AWMSG criteria for ultra orphan drug status.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 577), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at [www.evidence.nhs.uk](http://www.evidence.nhs.uk).

For full details on our accreditation visit: [www.nice.org.uk/accreditation](http://www.nice.org.uk/accreditation).

This recommendation has been ratified by the Minister for Health and Social Services and will be considered for review in three years.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 4014:  
Cabozantinib (Cometriq<sup>®</sup>▼) 20 mg and 80 mg hard capsules. December 2014.

